Blackstone Sells ZO Skin Health to Galderma for $1.5B
BX is trading near its 52-week low of $101.73 (8.3% above the low).
Summary
Blackstone Tactical Opportunities is selling ZO Skin Health to Galderma for $1.5 billion in cash. The deal values the physician-dispensed skincare brand at roughly 4.5x its $330 million trailing twelve-month net sales. Blackstone partnered with the Obagi family and more than doubled ZO's revenue during its ownership. The transaction is expected to close in Q4 2026 or early 2027, subject to regulatory approvals. This is a clean exit for Blackstone at a premium valuation, adding to its strong run of realizations this year.
At the time of this announcement, BX was trading at $110.20 on NYSE in the Finance sector, with a market capitalization of approximately $136.6B. The 52-week trading range was $101.73 to $166.39. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: BusinessWire.